256 related articles for article (PubMed ID: 8393043)
1. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes.
Finkelman FD; Madden KB; Morris SC; Holmes JM; Boiani N; Katona IM; Maliszewski CR
J Immunol; 1993 Aug; 151(3):1235-44. PubMed ID: 8393043
[TBL] [Abstract][Full Text] [Related]
2. Production of BSF-1 during an in vivo, T-dependent immune response.
Finkelman FD; Ohara J; Goroff DK; Smith J; Villacreses N; Mond JJ; Paul WE
J Immunol; 1986 Nov; 137(9):2878-85. PubMed ID: 3489779
[TBL] [Abstract][Full Text] [Related]
3. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo.
Sato TA; Widmer MB; Finkelman FD; Madani H; Jacobs CA; Grabstein KH; Maliszewski CR
J Immunol; 1993 Apr; 150(7):2717-23. PubMed ID: 8454851
[TBL] [Abstract][Full Text] [Related]
4. Exogenous interleukin 7 as a proliferative stimulant of early precursor B cells in mouse bone marrow: efficacy of IL-7 injection, IL-7 infusion and IL-7-anti-IL-7 antibody complexes.
Valenzona HO; Dhanoa S; Finkelman FD; Osmond DG
Cytokine; 1998 Jun; 10(6):404-12. PubMed ID: 9632525
[TBL] [Abstract][Full Text] [Related]
5. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo.
May LT; Neta R; Moldawer LL; Kenney JS; Patel K; Sehgal PB
J Immunol; 1993 Sep; 151(6):3225-36. PubMed ID: 8376777
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome.
Schurmans S; Heusser CH; Qin HY; Merino J; Brighouse G; Lambert PH
J Immunol; 1990 Oct; 145(8):2465-73. PubMed ID: 2212649
[TBL] [Abstract][Full Text] [Related]
7. CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production.
Lu P; Urban JF; Zhou XD; Chen SJ; Madden K; Moorman M; Nguyen H; Morris SC; Finkelman FD; Gause WC
J Immunol; 1996 May; 156(9):3327-33. PubMed ID: 8617957
[TBL] [Abstract][Full Text] [Related]
8. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro.
Maliszewski CR; Sato TA; Vanden Bos T; Waugh S; Dower SK; Slack J; Beckmann MP; Grabstein KH
J Immunol; 1990 Apr; 144(8):3028-33. PubMed ID: 2139075
[TBL] [Abstract][Full Text] [Related]
9. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor.
Fanslow WC; Clifford KN; Park LS; Rubin AS; Voice RF; Beckmann MP; Widmer MB
J Immunol; 1991 Jul; 147(2):535-40. PubMed ID: 1830065
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion.
Finkelman FD; Lees A; Birnbaum R; Gause WC; Morris SC
J Immunol; 1996 Aug; 157(4):1406-14. PubMed ID: 8759720
[TBL] [Abstract][Full Text] [Related]
11. In vivo administration of interleukin 1 elicits increased Ia antigen expression on B cells through the induction of interleukin 4.
Killar LM; Hatfield CA; Carding SR; Pan M; Winterrowd GE; Bottomly K
Eur J Immunol; 1989 Dec; 19(12):2205-10. PubMed ID: 2575031
[TBL] [Abstract][Full Text] [Related]
12. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
[TBL] [Abstract][Full Text] [Related]
13. The production of soluble interleukin 4 receptors is preferentially regulated by the murine Th2 cell subset.
Fernandez-Botran R; Chilton PM; Ma Y; Windsor JL; Street NE
Cytokine; 1997 Mar; 9(3):166-77. PubMed ID: 9126705
[TBL] [Abstract][Full Text] [Related]
14. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of interferon-gamma and interleukin-4, Th cell-derived cytokines by So-Shi-Ho-Tang (Sho-Saiko-To) occurs at the level of antigen presenting cells, but not CD4 T cells.
Kang H; Choi TW; Ahn KS; Lee JY; Ham IH; Choi HY; Shim ES; Sohn NW
J Ethnopharmacol; 2009 May; 123(1):6-14. PubMed ID: 19429332
[TBL] [Abstract][Full Text] [Related]
16. IL-4 induces loss of B lymphocyte Fc gamma R II ligand binding capacity.
Laszlo G; Dickler HB
J Immunol; 1988 Nov; 141(10):3416-21. PubMed ID: 2972773
[TBL] [Abstract][Full Text] [Related]
17. Selective stimulation of T cell subsets with antibody-cytokine immune complexes.
Boyman O; Kovar M; Rubinstein MP; Surh CD; Sprent J
Science; 2006 Mar; 311(5769):1924-7. PubMed ID: 16484453
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
Hihara J; Yamaguchi Y; Minami K; Noma K; Toge T
Anticancer Res; 1999; 19(2A):1077-84. PubMed ID: 10368657
[TBL] [Abstract][Full Text] [Related]
19. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors.
Brochier J; Liautard J; Jacquet C; Gaillard JP; Klein B
Eur J Immunol; 2001 Jan; 31(1):259-64. PubMed ID: 11265642
[TBL] [Abstract][Full Text] [Related]
20. Specific antagonism of type I IL-4 receptor with a mutated form of murine IL-4.
Schnare M; Blum H; Jüttner S; Röllinghoff M; Gessner A
J Immunol; 1998 Oct; 161(7):3484-92. PubMed ID: 9759868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
